Mood Stabilizer Medications: A Clinical Review

1. A Brief History of Mood Stabilizers

The history of mood stabilizers is largely a story of serendipity and pharmaceutical necessity. Each major agent was discovered through clinical observation or repurposing from other medical conditions, decades before mechanistic understanding emerged. This empirical approach remains the source of both psychiatric treatment's greatest triumphs and persistent gaps in our understanding.

2. Classes, Mechanisms, and Key Pharmacology

Lithium: The Simplest Psychiatric Medication

Lithium is a monovalent cation (Li+) and the simplest psychotropic drug: a naturally occurring element requiring no synthesis. Its mood-stabilizing mechanism remains incompletely understood, involving multiple intracellular pathways rather than a single pharmacological target.

• Inositol Monophosphatase (IMPase) Inhibition: The "inositol depletion hypothesis" (Berridge, 1989) proposes that lithium inhibits IMPase, depleting inositol and dampening overactive phosphatidylinositol signaling. This particularly affects cells with high membrane turnover, explaining both mood stabilization and some side effects.
• Glycogen Synthase Kinase-3β (GSK-3β) Inhibition: Lithium directly inhibits GSK-3β, promoting neuroprotection, upregulating BDNF (brain-derived neurotrophic factor), preventing apoptosis, and enhancing neuroplasticity. GSK-3β hyperactivity may contribute to bipolar pathophysiology.
• Glutamate Modulation: Lithium reduces excitatory glutamate neurotransmission, dampening overactive glutamatergic signaling implicated in mania.
• Circadian Rhythm Effects: Lithium modulates expression of circadian clock genes (CLOCK, BMAL1, Period), potentially stabilizing disrupted sleep-wake cycles that characterize mood cycling.
• Unique Anti-Suicide Properties: Lithium is the only psychiatric medication with demonstrated anti-suicidal effects independent of mood stabilization. Population studies of lithium in drinking water and randomized trials show reduced suicide risk even in non-responders to mood effects.

Pharmacokinetics: 100% oral bioavailability, zero protein binding, no hepatic metabolism, exclusively renal elimination. Steady-state achieved in 5–7 days. Half-life 18–36 hours (longer in elderly, shorter in young adults; pregnancy shortens it further). Narrow therapeutic index: 0.6–0.8 mEq/L for maintenance, 0.8–1.2 for acute mania, 0.4–0.6 for elderly.

Available Forms: Lithium carbonate (Eskalith, Lithobid) immediate-release and extended-release, lithium citrate liquid (easier dosing in children, better GI tolerance).

Valproate / Divalproex Sodium: The Potent Anticonvulsant

Valproate is a branched-chain fatty acid with multiple mechanisms of action, making it a "dirty drug" in modern pharmacology parlance — meaning it affects multiple targets, which accounts for both its efficacy and toxicity profile.

• GABAergic Enhancement: Inhibits GABA transaminase (reducing GABA catabolism) and enhances GABA synthesis, increasing inhibitory neurotransmission across the brain.
• Sodium Channel Blockade: Inhibits voltage-gated sodium channels, reducing neuronal firing rate and propagation — the primary anticonvulsant mechanism.
• Histone Deacetylase (HDAC) Inhibition: Epigenetic effects that increase histone acetylation, affecting gene expression related to neuroprotection and differentiation.
• MAPK/ERK Signaling Modulation: Affects extracellular signal-regulated kinase pathways involved in cell proliferation and survival.

Pharmacokinetics: Highly protein-bound (90%), hepatic metabolism via glucuronidation and mitochondrial β-oxidation. Half-life 9–16 hours (requires twice- or thrice-daily dosing with immediate-release; extended-release once daily). Therapeutic level 50–125 mcg/mL. Divalproex (Depakote) is a 1:1 combination of valproic acid and sodium valproate, providing better GI tolerance than valproate sodium alone.

Critical Safety Concern — Teratogenicity: Valproate is CONTRAINDICATED in pregnancy. Neural tube defects occur in 1–2% of exposed pregnancies (10–20 times baseline). More concerning, neurocognitive impairment in exposed children — reduced IQ, increased ADHD and autism spectrum disorder diagnosis, language delays — has emerged as a major long-term consequence.

Lamotrigine: The Antidepressant Mood Stabilizer

Lamotrigine is mechanistically distinct from other mood stabilizers and uniquely effective for bipolar depression rather than mania.

• Sodium Channel Blockade: Similar to carbamazepine but with distinct clinical effects; reduces frequency of action potentials and neurotransmitter release.
• Glutamate Release Inhibition: Reduces presynaptic glutamate and aspartate release, dampening excitatory neurotransmission.
• Calcium Channel Modulation: Inhibits high-voltage-activated calcium channels, further reducing neurotransmitter release.
• Serotonin Receptor Effects: Weak 5-HT3 antagonism and other serotonergic modulation may contribute to antidepressant properties.

The "Antidepressant Mood Stabilizer": Lamotrigine is the only mood stabilizer with primary efficacy against bipolar depression and depressive recurrence, making it unique in the class. It is less effective for acute mania treatment.

Pharmacokinetics: Hepatic glucuronidation by UGT1A4 is the primary metabolic pathway. Half-life 25 hours (dramatically affected by enzyme inducers/inhibitors): carbamazepine shortens to ~15 hours; valproate doubles to ~60 hours. No therapeutic blood level is established for psychiatric use. The half-life changes necessitate dose adjustments when combining with other medications.

CRITICAL — Stevens-Johnson Syndrome (SJS) Risk: SJS and toxic epidermal necrolysis (TEN) represent the most serious adverse effect. Risk is approximately 0.08% in adults (higher in children ~0.3%; higher with rapid titration; higher with concurrent valproate). The MANDATORY slow titration schedule reduces risk substantially: 25 mg/day for 2 weeks → 50 mg/day for 2 weeks → 100 mg/day for 1 week → target 200 mg/day. When used with valproate, halve all doses; with carbamazepine, double all doses. Any rash during titration requires immediate evaluation and discontinuation unless clearly non-drug-related.

Carbamazepine: Complex Pharmacology, Drug Interactions

Carbamazepine is effective in acute mania but encumbered by autoinduction and extensive drug interactions.

• Sodium Channel Blockade: Primary mechanism; structurally similar to phenytoin with broad anticonvulsant and mood-stabilizing effects.
• Glutamate Release Reduction: Decreases excitatory neurotransmission.
• Adenosine Receptor Antagonism: Modulates adenosine signaling, involved in circadian and sleep-wake regulation.

Pharmacokinetics — Autoinduction is Key: Carbamazepine is a potent inducer of CYP3A4, CYP1A2, and CYP2C9. Critically, it induces its own metabolism (autoinduction). Half-life decreases from 25–65 hours initially to 12–17 hours after weeks 3–5 of treatment. This means serum levels drop substantially over the first month, requiring monitoring and dose adjustment. Therapeutic level 4–12 mcg/mL.

Drug Interactions — A "Pharmacokinetic Nightmare": Carbamazepine reduces levels of oral contraceptives (contraceptive failure risk), warfarin, many antipsychotics (aripiprazole, lurasidone, quetiapine), lamotrigine, and valproate. This severely limits polypharmacy options. FDA-approved for acute manic and mixed episodes (not maintenance).

Safety Concerns:

• HLA-B*15:02 Testing: Mandatory before initiation in patients of Asian descent (Han Chinese, Thai, Filipino, Vietnamese, Malaysian, Indigenous North American); this allele carries 80-fold increased SJS/TEN risk. FDA black box warning.
• Aplastic Anemia and Agranulocytosis: Rare (~1 in 200,000) but serious; baseline CBC required, with monitoring during treatment.
• Hyponatremia (SIADH): Occurs in 5–10% of patients, occasionally severe; baseline sodium and periodic monitoring necessary.
• Hepatotoxicity: Rare but documented; baseline LFTs and periodic monitoring.
• Teratogenicity: Neural tube defects (0.5–1%) and craniofacial anomalies documented; lower risk than valproate but still significant.

Oxcarbazepine: A keto-derivative of carbamazepine with fewer drug interactions (does not induce CYP3A4), easier dosing, and better tolerability. However, evidence for bipolar disorder is limited compared to carbamazepine; primarily used off-label for maintenance or acute mania in patients unable to tolerate carbamazepine's interactions.

3. Evolving Indications and Clinical Evidence

FDA-Approved Indications by Agent

Off-Label but Evidence-Supported Uses

Lithium:

• Augmentation of antidepressants in treatment-resistant unipolar depression (Level A evidence; NNT ~5, one of psychiatry's best-studied augmentation strategies per Bauer & Döpfmer meta-analysis)
• Unique anti-suicidal effects independent of mood diagnosis or therapeutic response (demonstrated in ecological studies of lithium in water supply; active in randomized controlled trials)
• Schizoaffective disorder (augmentation of antipsychotics)
• Aggression and impulsivity reduction (separate from mood effects)
• Cluster headache prophylaxis

Valproate:

• Maintenance bipolar disorder (Level A evidence despite lack of FDA approval; widely used and most effective for rapid-cycling bipolar)
• Mixed features and rapid cycling (preferred over lithium for these presentations)
• Aggression and impulsivity in psychiatric populations
• Migraine prophylaxis (FDA-approved for this indication)
• PTSD (limited evidence)

Lamotrigine:

• Bipolar II disorder maintenance (though not FDA-approved specifically for bipolar II; evidence extrapolated from bipolar I trials; antidepressant effect is primary value)
• Borderline personality disorder with affective instability (limited evidence)
• Neuropathic pain (off-label use)

Carbamazepine:

• Trigeminal neuralgia (FDA-approved for this indication; distinct from psychiatric use)
• Neuropathic pain syndromes

Atypical Antipsychotics as Mood Stabilizers

The past 20 years have seen atypical antipsychotics (quetiapine, olanzapine, aripiprazole, lurasidone, cariprazine) obtain FDA approvals for various bipolar indications. Quetiapine has dual approval for acute mania AND bipolar depression. Olanzapine combined with fluoxetine (Symbyax) is approved for bipolar depression. Aripiprazole and cariprazine are approved for acute mania and maintenance. These agents are covered in detail in the Antipsychotics Review blog post; cross-reference rather than duplicate content here. Key point: atypical antipsychotics are now often first-line agents, particularly in acute mania and when psychotic features are present, partially displacing traditional mood stabilizers.

4. Side Effects Across Agents: A Comparative Analysis by Organ System

Renal System

Lithium is uniquely associated with renal complications. Nephrogenic diabetes insipidus (NDI) affects up to 40% of long-term lithium users, manifesting as polyuria and polydipsia. Chronic interstitial nephritis can gradually reduce glomerular filtration rate (GFR). Some GFR decline is expected with decades of lithium use; the rate varies by individual but averages ~5 mL/min per decade. Baseline renal function and regular monitoring are essential; patients must maintain adequate hydration and sodium intake.

Valproate, lamotrigine, and carbamazepine have no significant renal toxicity.

Thyroid System

Lithium causes hypothyroidism in 20–30% of patients, particularly women. Goiter, thyroid antibodies, and rarely hyperthyroidism are documented. TSH monitoring every 6 months is standard. Hypothyroidism can be managed through levothyroxine supplementation; if lithium is clinically necessary, thyroid replacement is preferred to discontinuation.

Other mood stabilizers have minimal thyroid effects.

Neurological

Lithium: Tremor (dose-dependent, affecting ~65% of users; often attenuated with time or propranolol), cognitive dulling/memory effects (subjectively reported; variable), cerebellar toxicity at toxic levels (ataxia, nystagmus, dysarthria — rare at therapeutic levels but hallmark of toxicity).

Valproate: Tremor (common, dose-dependent), sedation, encephalopathy (rare), pancreatitis-associated neurological symptoms.

Lamotrigine: Headache (often transient, rarely troublesome), dizziness (mild, usually during titration), diplopia (rare).

Carbamazepine: Ataxia, diplopia, dizziness, blurred vision, cognitive effects (particularly with prolonged use or autoinduction-related level fluctuations).

Weight and Metabolic Effects

Lithium: Moderate weight gain (average 4–10 kg); mechanism unclear but may involve altered glucose metabolism, ADH effects, and appetite stimulation.

Valproate: Significant weight gain (average 3–10+ kg), metabolic syndrome (insulin resistance, dyslipidemia), polycystic ovary syndrome risk in women. Weight gain is one of valproate's most troublesome side effects clinically.

Lamotrigine: Weight-neutral; a major clinical advantage. Some patients experience modest weight loss.

Carbamazepine: Modest weight gain, metabolic effects less pronounced than valproate.

Gastrointestinal

Lithium: Nausea (especially with immediate-release; mitigated by extended-release or dividing doses), diarrhea (can be limiting; treated with fiber, loperamide, or diet modification), dyspepsia.

Valproate: Nausea, vomiting, dyspepsia (mitigated by divalproex enteric-coated formulation), pancreatitis (rare but serious; can occur without elevation of liver enzymes; discontinue immediately if symptoms develop).

Lamotrigine: Nausea (usually mild, transient during titration).

Carbamazepine: Nausea, vomiting.

Hematologic

Valproate: Thrombocytopenia (dose-dependent; platelet count <100k occurs in ~5% of patients; platelet dysfunction may impair hemostasis disproportionate to count).

Carbamazepine: Leukopenia (benign in most cases; absolute neutrophil count mildly reduced but clinically insignificant), aplastic anemia (rare, ~1 in 200,000; requires baseline CBC and monitoring), agranulocytosis (rare).

Lithium: Leukocytosis (elevation of WBC; can be therapeutically exploited in clozapine-induced neutropenia; generally benign).

Dermatologic

Lamotrigine: Rash (including benign maculopapular rash and Stevens-Johnson Syndrome/TEN; discussed extensively in pharmacology section).

Lithium: Acne (can exacerbate pre-existing; retinoid treatment may be necessary), psoriasis exacerbation, hair changes, folliculitis.

Carbamazepine: SJS/TEN (particularly in HLA-B*15:02 carriers); DRESS syndrome (rare).

Hepatic

Valproate: Hepatotoxicity (rare fatal hepatic failure, primarily in children <2 years old on polypharmacy; estimated 1 in 500 in this age group; much rarer in adults); elevated transaminases common but usually benign and transient.

Carbamazepine: Hepatotoxicity (rare but documented).

Reproductive and Teratogenicity

Valproate: CONTRAINDICATED in pregnancy and women of childbearing potential (unless no alternatives). Neural tube defects in 1–2% (10–20 times baseline). Neurocognitive impairment in exposed children — reduced IQ, increased autism/ADHD, language delays — affects 30–40% of exposed offspring. Risk increases with dose and first-trimester exposure.

Carbamazepine: Neural tube defects (0.5–1% risk) and craniofacial anomalies (cleft palate, cardiac defects, urogenital abnormalities) documented. Lower teratogenicity risk than valproate but still significant.

Lithium: Ebstein's anomaly (cardiac: atrial septal defect and other right-side cardiac malformations) was historically estimated at 1 in 20 from early retrospective registries (Salzburg Register); modern meta-analyses and prospective studies show actual risk is approximately 1 in 1,000 — the original estimates were dramatically overestimated due to ascertainment bias. Risk is no longer considered a contraindication to pregnancy with informed consent and fetal echocardiography. Diabetes insipidus in exposed neonates (usually transient).

Lamotrigine: Safest mood stabilizer in pregnancy. Registry data shows no significant increase in major malformations at doses ≤200 mg; data at higher doses is more limited. Preferred agent in pregnant patients requiring mood stabilization.

5. Choosing the Right Mood Stabilizer: Clinical Decision Framework

Acute Mania

First-line agents: lithium or valproate (both Level A evidence). Lithium is preferred for classic/euphoric mania with intact insight. Valproate may be preferred for mixed features, rapid cycling, or when faster onset is needed (loading strategies possible with valproate; not with lithium). Adjunctive antipsychotic is standard for severe mania or psychotic features. Typical treatment duration: 2–4 weeks to full response. Maintenance therapy begins immediately after acute stabilization.

Bipolar Depression

First-line: lamotrigine (for moderate, non-urgent depression; full effect requires weeks of titration). Alternatively, quetiapine or lurasidone (atypical antipsychotics with FDA bipolar depression approval; faster onset than lamotrigine). Lithium has moderate antidepressant effects. Valproate has limited evidence for acute bipolar depression. CRITICAL: Avoid antidepressant monotherapy in bipolar disorder without mood stabilizer/antipsychotic cover due to manic switch risk (5–30% depending on bipolar subtype and baseline mood state).

Maintenance / Prophylaxis

Lithium remains the gold standard for preventing both manic and depressive recurrence; best evidence base. Lamotrigine is first-line for preventing depressive recurrence specifically. Valproate is preferred for mixed/rapid cycling maintenance. Combination (lithium + lamotrigine) is an evidence-supported approach for patients with both manic and depressive recurrences. Monotherapy response rates: lithium ~50%, valproate ~50–60%, lamotrigine ~40–50% (but higher for depression prevention).

Rapid Cycling Bipolar Disorder

Valproate is often preferred over lithium (lithium less effective in rapid cycling; mechanism unknown). Rule out secondary causes: thyroid dysfunction, substance use, antidepressant-induced cycling. Consider combination with lamotrigine if depressive-predominant cycling.

Women of Childbearing Potential

Lamotrigine is the clear first choice (safest teratogenicity profile; no contraindication to pregnancy). Avoid valproate if possible; if essential, comprehensive informed consent, effective contraception, and preconception counseling required. Lithium with informed consent, target lower levels (0.4–0.6 mEq/L during pregnancy), and fetal echocardiography in first trimester.

Treatment-Resistant Unipolar Depression

Lithium augmentation of antidepressants is Level A evidence (Bauer & Döpfmer meta-analysis: NNT ~5). One of psychiatry's best-studied augmentation strategies. Target serum level 0.6–0.8 mEq/L. Response typically within 2–4 weeks; if no response by week 4, consider alternative augmentation.

Significant Suicidality (Any Diagnosis)

Lithium should be considered even in non-bipolar patients with significant suicide risk due to its unique anti-suicidal properties demonstrated independent of mood stabilization. Effective even at sub-therapeutic doses in some studies. No other psychiatric medication has this evidence base.

6. Monitoring Protocols by Agent

Lithium Monitoring

Baseline Assessment: Renal function (BMP/BUN/creatinine, urinalysis for concentrating ability), thyroid function (TSH, free T4), serum calcium, CBC, pregnancy test (women of childbearing potential), ECG (if cardiac history or age >40).

Lithium Levels: First level at 5 days post-initiation (approximate steady state). Target: 0.6–0.8 mEq/L maintenance, 0.8–1.2 acute mania, 0.4–0.6 elderly. Draw trough (12 hours post-dose). Recheck with every dose change, then every 3 months first year, then every 6 months.

Ongoing Monitoring: Lithium level + BMP every 3 months first year, then every 6 months. TSH every 6 months. Serum calcium and renal function (creatinine, eGFR) annually. Urinalysis annually to assess concentrating ability.

Toxicity Levels: >1.5 mEq/L = mild-moderate toxicity; >2.0 = moderate-severe; >2.5 = severe/life-threatening.

Valproate Monitoring

Baseline: CBC with differential and platelets, LFTs, lipase/amylase (pancreatitis baseline), coagulation studies, pregnancy test.

Valproate Levels: Therapeutic range 50–125 mcg/mL (85–125 for acute mania). Draw trough. Levels are less predictive of mood response than lithium; primarily used to guide dosing and toxicity assessment.

Ongoing Monitoring: CBC + LFTs every 3 months first year, then every 6–12 months. Weight every 3–6 months (monitor for metabolic syndrome). Menstrual history in women (PCOS screening). Pantothenic acid (vitamin B5) supplementation may reduce hair loss.

Lamotrigine Monitoring

No routine blood level monitoring required. Therapeutic blood levels have not been established for psychiatric use (unlike neurology).

Critical — Rash Monitoring During Titration: Assess for rash at every visit during the first 8 weeks (entire titration period). Patient education on rash recognition and emergency department presentation is essential. Any rash requires evaluation; discontinue unless clearly non-drug-related.

Dose Adjustments for Drug Interactions: If used with valproate (inhibits glucuronidation), halve all doses. If used with carbamazepine (induces glucuronidation), double all doses.

Carbamazepine Monitoring

Baseline: HLA-B*15:02 testing MANDATORY (FDA black box warning) for patients of Asian descent. CBC with differential, LFTs, BMP (sodium), pregnancy test.

Carbamazepine Levels: Therapeutic range 4–12 mcg/mL. Remember autoinduction: recheck levels at weeks 4–6 and adjust dose accordingly (levels will drop substantially).

Ongoing Monitoring: CBC, LFTs, sodium, and carbamazepine level every 3 months first year (due to autoinduction requiring adjustment), then every 6 months. Drug interaction check at every new prescription to another medication (CYP3A4 induction affects many agents).

7. Toxicity and Medical Emergencies

Lithium Toxicity

Common Causes: Dehydration (vomiting, diarrhea, excessive heat), NSAIDs (reduce renal clearance), ACE inhibitors/ARBs (reduce renal clearance), thiazide diuretics (reduce renal clearance), renal impairment, dose error.

Clinical Presentation by Severity:

• Mild (1.5–2.0 mEq/L): Increased tremor, nausea, diarrhea, blurred vision, dizziness, drowsiness
• Moderate (2.0–2.5 mEq/L): Confusion, ataxia, dysarthria, nystagmus, vomiting, muscle fasciculations, hyperreflexia
• Severe (>2.5 mEq/L): Seizures, coma, cardiac arrhythmias, renal failure, death

Management: Discontinue lithium immediately. Initiate aggressive IV normal saline rehydration. Correct electrolyte abnormalities (check sodium, potassium, magnesium). Hemodialysis is indicated for: lithium level >4.0 mEq/L, level >2.5 with impaired renal function, severe neurological symptoms (seizures, coma, severe ataxia), or rising levels despite conservative management. NOTE: Lithium redistributes into tissues; rebound elevation of serum levels 4–6 hours after dialysis is common; repeat dialysis may be necessary.

SIND (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity): A rare but devastating complication characterized by persistent cerebellar dysfunction, cognitive impairment, downbeat nystagmus, and personality changes that persist even after lithium levels normalize. Risk increases with chronic toxicity and delayed treatment. Some patients recover partially over months; others have permanent deficits. Prevention through careful monitoring and early treatment of toxicity is paramount.

Valproate Toxicity

Hepatic Failure: Rare fatal hepatic failure occurs primarily in children <2 years old on polypharmacy (estimated 1 in 500 in this age group; much rarer in adults and adolescents). Risk factors: polypharmacy, family history of mitochondrial disease, prior adverse drug reactions. Monitor LFTs closely, particularly in the first 6 months.

Acute Pancreatitis: Idiopathic pancreatitis occurs in ~1 in 500 to 1 in 1,000 patients. Can occur at any time during treatment. Presents with abdominal pain, nausea, elevated amylase/lipase. Immediate discontinuation required.

Hyperammonemic Encephalopathy: Can occur WITHOUT elevated LFTs or ammonia levels initially. Presents with confusion, lethargy, ataxia. Check ammonia level in any patient on valproate with altered mental status. Discontinue valproate if hyperammonia is confirmed; carnitine supplementation may help.

Carbamazepine Toxicity

Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis: Serious dermatologic emergency; mandatory HLA-B*15:02 testing before initiation in at-risk patients reduces incidence. Any rash requires immediate evaluation and likely discontinuation.

Aplastic Anemia: Rare but serious; baseline CBC required with periodic monitoring.

Severe Hyponatremia (SIADH): Sodium <125 can present with confusion, seizures, cerebral edema. Discontinue carbamazepine; manage hyponatremia carefully (hypertonic saline in acute, severe cases; fluid restriction otherwise).

Drug Interaction Toxicity: Carbamazepine's CYP3A4 induction can reduce levels of other critical medications (oral contraceptives, warfarin, antipsychotics), potentially causing therapeutic failure.